Related Experiment Video
Updated: Jun 1, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
The microfocus assay system (mfas) - a simple quantitative assay to identify inhibitory drugs targeted against
1UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030. UNIV TEXAS,HLTH SCI CTR,GRAD SCH BIOMED SCI,HOUSTON,TX 77030.
Abstract:
We have developed an assay, the microfocus assay system (MFAS), that enables the quantitative assessment of anticancer drugs and their ability to specifically target and inhibit cellular oncogenes. Analysis of three chemotherapeutic reagents showed a differential negative effect against the ability of transformed cells containing either the oncogenic rat neu, human H-ras, or v-mos oncogene to form transformed foci on a background of normal fibroblasts. Though these drugs have not been examined previously for targeting against specific oncogenes, our results with the MFAS indicate preferential inhibitory effects against cells transformed with different oncogenes. Therefore, the MFAS should enable the large scale screening of anti-cancer drugs specifically targeted against known oncogenes and provide a quantitative measurement of their effectiveness.
Insights
A new assay, the microfocus assay system (MFAS), quantifies anticancer drugs targeting oncogenes. MFAS revealed differential drug effects on cells with specific oncogenes, enabling targeted drug screening.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Oncogenes drive cancer development.
- Targeting specific oncogenes is a key strategy in cancer therapy.
- Existing assays lack the specificity to evaluate drugs against individual oncogenes.
Purpose of the Study:
- To develop and validate a novel assay, the microfocus assay system (MFAS), for quantifying the inhibitory effects of anticancer drugs on oncogene-driven cellular transformation.
- To assess the ability of MFAS to differentiate the effects of chemotherapeutic agents on cells transformed by specific oncogenes (rat neu, human H-ras, v-mos).
Main Methods:
- Development of the microfocus assay system (MFAS) for quantitative assessment.
- Analysis of three chemotherapeutic reagents using MFAS.
- Evaluation of drug effects on transformed cells containing specific oncogenes (rat neu, human H-ras, v-mos) versus normal fibroblasts.
Main Results:
- MFAS successfully enabled quantitative assessment of anticancer drugs targeting oncogenes.
- Analysis revealed differential inhibitory effects of tested drugs against cells transformed by different oncogenes.
- The assay demonstrated preferential inhibition against cells with specific oncogenes, indicating targeted activity.
Conclusions:
- The microfocus assay system (MFAS) is a valuable tool for evaluating anticancer drug efficacy.
- MFAS facilitates the large-scale screening of drugs for targeted inhibition of specific oncogenes.
- This assay provides quantitative measurements crucial for developing targeted cancer therapies.
